Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
GeNeuro
Biotech
GeNeuro's long COVID trial fails, triggering layoffs
GeNeuro reported the near-total failure of the phase 2 trial, telling investors it saw no effect on the primary endpoint and most secondary goals.
Nick Paul Taylor
Jun 28, 2024 5:34am
How GeNeuro's experimental MS drug might help treat COVID-19
Apr 15, 2021 1:30am
GeNeuro raises €17.5M for multiple sclerosis clinical trial
Jan 31, 2020 8:35am
Servier drops GeNeuro’s MS drug after midphase miss
Sep 18, 2018 4:28am
Bucking a negative trend, Servier-backed GeNeuro gets off its IPO
Apr 15, 2016 8:25am
